Latest News

Date Title Topic
14 Aug 2017 The EU needs a more coherent research funding landscape Bioethics, legal and economic issues
11 Aug 2017 ESMO 2017 Press Release: Sneak Peek into the ESMO 2017 Press Programme
11 Aug 2017 FDA Grants Nivolumab Accelerated Approval for MSI-H or dMMR Colorectal Cancer Cancer in Special Situations - Gastrointestinal cancers - Cancer Immunology and Immunotherapy
10 Aug 2017 FDA Accepts Applications for Nivolumab Four Week Dosing Schedule Across All Approved Indications Cancer Immunology and Immunotherapy
08 Aug 2017 EMA Recommends Refusal of the Marketing Authorisation for Etirinotecan Pegol Breast cancer - Anticancer agents & Biologic therapy
08 Aug 2017 Response Evaluation and Biomarker Development in Onco-Immunology
07 Aug 2017 EMA Adopts a New Indication for Obinutuzumab Haematologic malignancies - Anticancer agents & Biologic therapy
Webcasts
04 Aug 2017 EMA Recommends Granting a Marketing Authorisation for Telotristat Ethyl Endocrine and neuroendocrine tumours
03 Aug 2017 Translational Research Unit Visit 2017
03 Aug 2017 Guide for Patients in Bone Sarcomas Now Available Also in Japanese
03 Aug 2017 EMA Recommends Granting a Marketing Authorisation for Avelumab Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
03 Aug 2017 Press Release: CAREFOR Calls on EU to Safeguard Independent Academic Research
02 Aug 2017 Immune Contexture of Cancer
31 Jul 2017 FDA Expands Approval of Ipilimumab to Include Paediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma Cancer in Special Situations - Melanoma and other skin tumours - Cancer Immunology and Immunotherapy